Overall Survival (OS) Update: 2-year follow-up from the phase-3 RESORCE trial of Regorafenib for patients with hepatocellular carcinoma (HCC) progressing on Sorafenib — D. Waldschmidt (2019) | RDL Network
Overall Survival (OS) Update: 2-year follow-up from the phase-3 RESORCE trial of Regorafenib for patients with hepatocellular carcinoma (HCC) progressing on Sorafenib
Article 2019 en
Authors
DW
D. Waldschmidt
AG
Alessandro Granito
PM
Philippe Merle
Abstract
1 min read
In the phase 3 RESORCE trial, regorafenib improved OS compared with placebo in patients with unresectable HCC who progressed during sorafenib treatment. The most common regorafenib-related adverse events were hand-foot skin reaction, diarrhea, fatigue, hypertension, and anorexia, consistent with the known safety profile of regorafenib. We present an updated OS analysis from RESORCE, nearly 2 years after the primary analysis.
Jordi Bruix, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gerolami, Gianluca Masi, Paul J. Ross, Shukui Qin, Tianqiang Song, Jean‐Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Lei Xu, Annette Baumhauer, Gerold Meinhardt, Guohong Han
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gérolami, Gianluca Masi, Paul J. Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Ann‐Lii Cheng, Josep M. Llovet, Richard S. Finn, Marie-Aude LeBerre, ,
Jordi Bruix, Jean‐Luc Raoul, Morris Sherman, Vincenzo Mazzaferro, Luigi Bolondi, Antonio Craxı̀, Peter R. Galle, Armando Santoro, Michel Beaugrand, Angelo Sangiovanni, Camillo Porta, Guido Gerken, Jorge A. Marrero, Andrea Nadel, Michael Shan, M. Moscovici, D. Voliotis, Josep M. Llovet
Discussion(0)
No comments yet. Be the first to comment.